1708-P: Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ≥25 kg/m2—A Six-Month Real-World Study

Overweight and obesity are increasingly recognized as potential targets for early intervention. Unlike injectable treatments, oral formulations are more easily accepted by people with diabetes. In Asian Indians, BMI ≥ 25 kg/m2 is considered obesity. Study participants were de-identified from the electronic medical records of a comprehensive diabetes centre in Kerala, India. The primary outcome variables were assessed at baseline and again at 6 months. Subjects with data spanning from March 2022 to July 2023 and a BMI ≥ 25 kg/m2 were included in the study. Those without follow-up data were excluded. Over six months, oral semaglutide (N=221) significantly reduced HbA1c by 1.38% (95% CI = 0.7 to 2.1, p 0.001) in T2DM with BMI ≥ 25 kg/m2. A significant reduction was observed with a Mean Absolute Difference (MAD) of 2.2 kg/m2 in BMI (95% CI = 1.1 to 3.3, p 0.001) and 4.76 kg in weight (95% CI = 2.7 to 6.8, p 0.001). 27 participants (8%) discontinued due to side effects. (Figure). In this real world study 1 in 3 T2D with obesity achieved a weight loss of 5% and 1 in 2 T2D with obesity achieved reduction in insulin dose. This study provides real-world evidence of sustainable improvements in A1C, weight, and BMI among T2D treated with oral semaglutide. Disclosure J. Kesavadev: None. A. Shankar: None. B.D. Saboo: None. A. Ashik: None. J. Naina: None. K. Jothydev: None. A. Basanth: None. S. Raj K: None. S. Jothydev: None.